Progenics Pharmaceuticals Inc (PGNX) investors sentiment increased to 1.22 in 2017 Q4. It’s up 0.11, from 1.11 in 2017Q3. The ratio increased, as 62 investment managers started new or increased positions, while 51 cut down and sold holdings in Progenics Pharmaceuticals Inc. The investment managers in our database now hold: 56.89 million shares, down from 58.90 million shares in 2017Q3. Also, the number of investment managers holding Progenics Pharmaceuticals Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 11 Reduced: 40 Increased: 40 New Position: 22.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Ratings Coverage
Ratings analysis reveals 100% of Progenics Pharm’s analysts are positive. Out of 2 Wall Street analysts rating Progenics Pharm, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. PGNX was included in 2 notes of analysts from October 27, 2016. The company was initiated on Thursday, October 27 by Aegis Capital. On Monday, February 6 the stock rating was upgraded by Needham to “Strong Buy”.
The stock decreased 2.93% or $0.22 during the last trading session, reaching $7.3. About 956,953 shares traded. Progenics Pharmaceuticals, Inc. (PGNX) has declined 32.66% since May 18, 2017 and is downtrending. It has underperformed by 44.21% the S&P500.
Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company has market cap of $538.15 million. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen -targeted positron emission topography (PET) imaging agent for prostate cancer. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products.
Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on August, 8. They expect $-0.19 earnings per share, up 20.83% or $0.05 from last year’s $-0.24 per share. After $-0.19 actual earnings per share reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Ardsley Advisory Partners holds 1.32% of its portfolio in Progenics Pharmaceuticals, Inc. for 1.83 million shares. Phocas Financial Corp. owns 1.44 million shares or 0.72% of their US portfolio. Moreover, Rice Hall James & Associates Llc has 0.32% invested in the company for 1.38 million shares. The New York-based Sio Capital Management Llc has invested 0.28% in the stock. Pinnacle Associates Ltd, a New York-based fund reported 2.21 million shares.
More recent Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) news were published by: Seekingalpha.com which released: “Progenics Earnings: Get Ready For A Massive Move” on May 10, 2018. Also Seekingalpha.com published the news titled: “Progenics Pharmaceuticals’ (PGNX) CEO Mark Baker on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018. Globenewswire.com‘s news article titled: “Progenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update” with publication date: May 09, 2018 was also an interesting one.
The stock increased 0.09% or $0.03 during the last trading session, reaching $31.67. About 837,505 shares traded. Integrated Device Technology, Inc. (NASDAQ:IDTI) has risen 30.43% since May 18, 2017 and is uptrending. It has outperformed by 18.88% the S&P500.
Chris Allexandre, an insider and also SR. VP of GLOBAL SALES & MARKE of the leading company Integrated Device Technology Inc made trade. He unloaded 3,661 shares of the corporation with Chris Allexandre’s sale worth approx. $112,759 U.S. Dollars – calculated based on $30.8 per every share. Now, he holds a total of 74,724 shares or 0.06% of the Company’s market cap.
Investors sentiment decreased to 0.83 in 2017 Q4. Its down 0.28, from 1.11 in 2017Q3. It fall, as 24 investors sold Integrated Device Technology, Inc. shares while 94 reduced holdings. 41 funds opened positions while 57 raised stakes. 124.57 million shares or 6.44% less from 133.15 million shares in 2017Q3 were reported. Teacher Retirement Systems Of Texas stated it has 45,948 shares. Vantage Investment Advsr Limited Liability reported 500 shares stake. 4,700 were reported by Pacad Investment Ltd. Sandy Spring Fincl Bank has 0% invested in Integrated Device Technology, Inc. (NASDAQ:IDTI) for 187 shares. Cornerstone Cap Management Lc holds 0% or 1,000 shares in its portfolio. Royal Fincl Bank Of Canada accumulated 0.01% or 394,502 shares. 959,680 are held by Hodges Mngmt. Laurion Cap Mngmt Limited Partnership accumulated 22,900 shares or 0% of the stock. Canada Pension Plan Investment Board has invested 0% in Integrated Device Technology, Inc. (NASDAQ:IDTI). Foundry Ptnrs Lc holds 0.08% of its portfolio in Integrated Device Technology, Inc. (NASDAQ:IDTI) for 67,641 shares. Georgia-based Invesco Limited has invested 0.04% in Integrated Device Technology, Inc. (NASDAQ:IDTI). State Street has 4.85M shares for 0.01% of their portfolio. 100 are held by Hanson Mcclain. Benjamin F Edwards Inc has 350 shares for 0% of their portfolio. Gemmer Asset Mngmt Ltd invested 0% in Integrated Device Technology, Inc. (NASDAQ:IDTI).
Since December 14, 2017, it had 0 buys, and 16 sales for $7.24 million activity. Another trade for 2,721 shares valued at $87,290 was made by Allexandre Chris on Thursday, March 15. $705,210 worth of stock was sold by MONTANA MARIO on Thursday, March 8. 15,583 shares valued at $514,239 were sold by WHITE BRIAN C on Friday, January 19. Shares for $492,196 were sold by WATERS GREGORY L on Friday, February 16. Chittipeddi Sailesh also sold $123,392 worth of Integrated Device Technology, Inc. (NASDAQ:IDTI) on Tuesday, April 17. Shepard David also sold $682,222 worth of Integrated Device Technology, Inc. (NASDAQ:IDTI) on Thursday, December 14.
Integrated Device Technology, Inc. designs, develops, makes, and markets a range of semiconductor solutions for the communications, computing, consumer, automotive, industrial, and Internet-of-things end-markets. The company has market cap of $4.19 billion. It operates in two divisions, Communications; and Computing, Consumer, and Industrial. It currently has negative earnings. The Communications segment offers clocks and timing solutions; flow-control management devices comprising Serial RapidIO switching solutions; multi-port products; telecommunications products; static random access memory products; first in and first out memories; digital logic products; radio frequency products; and frequency control solutions.
Analysts await Integrated Device Technology, Inc. (NASDAQ:IDTI) to report earnings on July, 30. They expect $0.35 earnings per share, up 40.00% or $0.10 from last year’s $0.25 per share. IDTI’s profit will be $46.32 million for 22.62 P/E if the $0.35 EPS becomes a reality. After $0.39 actual earnings per share reported by Integrated Device Technology, Inc. for the previous quarter, Wall Street now forecasts -10.26% negative EPS growth.
Among 20 analysts covering Integrated Device (NASDAQ:IDTI), 18 have Buy rating, 0 Sell and 2 Hold. Therefore 90% are positive. Integrated Device has $40.0 highest and $19 lowest target. $32.06’s average target is 1.23% above currents $31.67 stock price. Integrated Device had 52 analyst reports since August 4, 2015 according to SRatingsIntel. Roth Capital maintained the shares of IDTI in report on Sunday, July 30 with “Buy” rating. The firm has “Buy” rating by Charter Equity given on Monday, October 26. Barclays Capital maintained it with “Underweight” rating and $19 target in Tuesday, August 2 report. Needham maintained the stock with “Buy” rating in Tuesday, August 1 report. The company was upgraded on Tuesday, February 2 by Wedbush. On Monday, February 8 the stock rating was maintained by Chardan Capital Markets with “Buy”. As per Monday, May 23, the company rating was initiated by Brean Capital. Bank of America downgraded the stock to “Underperform” rating in Tuesday, August 1 report. The company was maintained on Tuesday, October 27 by Dougherty & Company. The firm has “Buy” rating given on Tuesday, May 1 by Needham.